NaiyerARizviMD

Oncology • New York, NY

Thoracic Cancer

Professor of Medicine, Columbia University Medical Center

Join to view full profile

Dr. Rizvi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rizvi's full profile

Already have an account?

Office
1275 York Ave
New York, NY 10065
Phone+1 646-227-3813

Fax+1 212-305-3035

Education & Training

Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 1990 - 1995
University of ManitobaClass of 1987

Certifications & Licensure

NY State Medical License 2002 - 2025
DC State Medical License 1995 - 2002
VA State Medical License 1996 - 2002

Awards, Honors, & Recognition

Top Doctors: New York Metro Area Castle Connolly, 2008-2014

Clinical Trials

Inhaled Doxorubicin in Treating Patients With Primary Lung Cancer or Lung Metastases Start of enrollment: 1999 Jul 01
Completed
Phase 1
10-Propargyl-10-Deazaaminopterin Plus Probenecid in Treating Patients With Advanced Solid Tumors Start of enrollment: 2001 May 01
Completed
Phase 1
ABI-007 in Treating Patients With Chemotherapy-Naïve Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2003 Sep 01
Completed
Phase 1, Phase 2
Epothilone D in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Platinum-Based Chemotherapy Start of enrollment: 2003 Dec 01
Completed
Phase 2
Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors Start of enrollment: 2004 Mar 01
Completed
Phase 1
Safety and Pharmacokinetics of Jin Fu Kang in Comb w/Docetaxel for Patients w/Non-Small Cell Lung Cancer Start of enrollment: 2004 Nov 01
Completed
Phase 2
Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene Start of enrollment: 2004 Jun 01
Completed
Phase 2
Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. Start of enrollment: 2015 Jun 17
Completed
Phase 1, Phase 2
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer Start of enrollment: 2015 Jul 01
Completed
Phase 1
Genetic Predictors of Benefit to Pembrolizumab Start of enrollment: 2016 May 31
Terminated
Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe) Start of enrollment: 2019 Mar 11
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

2182 citations
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan, Andrew Furness, Rachel Rosenthal, Sofie Ramskov, Rikke Birgitte Lyngaa
Science. 2016-03-25
92 citations
Phase II Trial of Neoadjuvant Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with Resectable Nonsquamous Non–Small-Cell Lung Cancers
Jamie E. Chaft, Valerie W. Rusch, Michelle S. Ginsberg, Paul K. Paik, David J. Finley
Journal of Thoracic Oncology. 2013-08-01
4492 citations
Pembrolizumab for the treatment of non-small cell lung cancer
Edward B. Garon, Naiyer A. Rizvi, Rina Hui, Natasha B. Leighl, Ani Sarkis Balmanoukian
The New England Journal of Medicine. 2015-05-20

Journal Articles

Differential Regulation of PD-L1 Expression by Immune and Tumor Cells in NSCLC and the Response to Treatment with Atezolizumab (Anti–PD-L1)
Alan Sandler, David S Shames, Hartmut Koeppen, Jamie Chaft, Scott N Gettinger, Alexander Spira, Daniel S Chen, Naiyer A Rizvi, David R Spigel, Proceedings of the National Academy of Sciences

Lectures

Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) Â± tremelimumab (T) versus chemotherapy ...
2019 ASCO Annual Meeting - 6/1/2019
Lung Cancer. Integrating Immunotherapy Into Clinical Practice: Changes Over the Past Year (Part 1)
2018 ASCO Annual Meeting - Chicago, Illinois - 05/31/2018

Press Mentions

As Biotech Debates Vaccine Mandates, One CEO Tries to Convince the 3% That Got AwayAugust 11th, 2021
Synthekine Scores Major $108M B Round to Secure Set of Trials in 12 MonthsJune 10th, 2021
Investors Pile on Stanford Spinout Promising New Ways to Attack Cancer, Autoimmune DiseasesJune 10th, 2021
Join now to see all

Grant Support

Early Clinical Trials Of New Anti-Cancer Agents With Phase 1 EmphasisNational Cancer Institute2008
Phase I Clinical Trials Of Novel AgentsNational Cancer Institute2006–2007
Foreign Accrual For 5u10ca069856 2006 Load Phase I U01 Rizvi MskiNational Cancer Institute2006
Correlation Of EGFR Mutations And Response To GefitinibNational Cancer Institute2005–2006
Pv701 Safety/Efficacy In Advanced/Recurrent Solid TumorsNational Center For Research Resources2000
Oral Dose Escalation Of Tac-101 In Advanced MalignanciesNational Center For Research Resources2000
Oral BMS-275291 Metalloproteinase Inhibitor In CancerNational Center For Research Resources2000